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Summary
Linoleic acid (LA) is the most abundant polyunsaturated fatty acid in human diets, a major
component of human tissues, and the direct precursor to the bioactive oxidized LA metabolites
(OXLAMs), 9- and 13 hydroxy-octadecadienoic acid (9- and 13-HODE) and 9- and 13-oxo-
octadecadienoic acid (9- and 13-oxoODE). These four OXLAMs have been mechanistically
linked to pathological conditions ranging from cardiovascular disease to chronic pain. Plasma
OXLAMs, which are elevated in Alzheimer’s dementia and non-alcoholic steatohepatitis, have
been proposed as biomarkers useful for indicating the presence and severity of both conditions.
Because mammals lack the enzymatic machinery needed for de novo LA synthesis, the abundance
of LA and OXLAMs in mammalian tissues may be modifiable via diet. To examine this issue in
humans, we measured circulating LA and OXLAMs before and after a 12-week LA lowering
dietary intervention in chronic headache patients. Lowering dietary LA significantly reduced the
abundance of plasma OXLAMs, and reduced the LA content of multiple circulating lipid fractions
that may serve as precursor pools for endogenous OXLAM synthesis. These results show that
lowering dietary LA can reduce the synthesis and/or accumulation of oxidized LA derivatives that
have been implicated in a variety of pathological conditions. Future studies evaluating the clinical
implications of diet-induced OXLAM reductions are warranted.
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Introduction
Oxidized linoleic acid metabolites (OXLAMs) are pleiotropic bioactive derivatives of
linoleic acid (LA, 18:2n-6) that have been implicated in a variety of pathological conditions
[1,2,3,4,5,6,7,8,9]. As a major component of oxidized low-density lipoprotein (LDL)
[7,10,11] and atherosclerotic plaques [12,13], OXLAMs are reported to play a central role in
foam cell formation and the pathogenesis of atherosclerosis [4,8,14]. OXLAMs also can act
as endogenous TRPV1 receptor channel activators (i.e. endovanilloids)[1,2], facilitating
peripheral and central pain sensitization. Circulating OXLAMs, which are elevated in
Alzheimer’s dementia [15] and non-alcoholic steatohepatitis (NASH)[3], have been
proposed as mechanism-based biomarkers useful for indicating the presence and severity of
both conditions.
LA is the most abundant polyunsaturated fatty acid in human diets [16,17,18], a major
component of human tissues, and the direct precursor to the OXLAMs 9- and 13- hydroxy-
octadecadienoic acid (9- and 13-HODE) and 9- and 13-oxo-octadecadienoic acid (9- and 13-
oxoODE)[19] (Fig.1). LA oxidation can proceed enzymatically via the actions of 12/15-
lipoxygenase, cyclooxygenase or the cytochrome P450 enzyme family [19,20], or non-
enzymatically via free radical-mediated oxidation [21].
Because humans cannot synthesize LA de novo [17,22,23], dietary LA is the sole source of
LA in blood and other tissues. These LA stores in turn serve as precursor pools for
endogenous OXLAM synthesis. Hence, diet-induced reductions in LA content may
subsequently decrease the abundance of OXLAMs in vivo, with potential implications for
conditions characterized by TRPV1 hyperactivity (e.g. chronic pain), as well as
cardiovascular, hepatic and neurodegenerative diseases. To our knowledge, however, the
relationship between dietary LA and plasma OXLAMs has not been reported in humans.
We hypothesized that lowering dietary LA would reduce plasma OXLAMs as well as their
precursor LA in circulating lipid pools, in humans with chronic headaches.
Materials and Methods
Patient characteristics
This study was approved by the Institutional Review Board of the University of North
Carolina-Chapel Hill. All patients provided written informed consent prior to participation.
The cohort consisted of 67 subjects meeting the International Classification of Headache
Disorders diagnostic criteria for Chronic Daily Headache [24]. Fifty-six of 67 (84%)
randomized subjects completed the 12-week intervention phase. The mean age at
randomization was 41.3 (range 20-62; SD 11.5). Eighty-five percent of randomized subjects
were female and 88% were Caucasian.
Study Design
The main study was designed to evaluate the effects of lowering dietary LA, with or without
concurrent increases in n-3 PUFAs, on plasma and erythrocyte fatty acids (primary
outcomes) and clinical headache characteristics (secondary outcomes)(21). These outcomes
will be reported in another publication. However, after our trial was already in progress,
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OXLAMs were implicated in the etiology of physical pain (1-2), and proposed as
mechanism-based biomarkers in NASH (3). Recognizing that our LA lowering interventions
provided a unique opportunity to evaluate whether diet-induced OXLAM reductions are
possible in humans, we developed an interdisciplinary collaboration to specifically evaluate
whether lowering dietary LA reduces plasma OXLAMs as well as their precursor LA in
circulating lipid pools.
The dietary methods and methods employed to evaluate LA intake have been previously
published [24]. In brief, after a 4-week baseline phase participants were randomized to one
of two dietary interventions, to be maintained for 12 consecutive weeks. Both interventions
were designed to markedly reduce LA intake. Group 1 consumed average US amounts of
n-3 fatty acids; Group 2 also increased intake of n-3 fatty acids as shown in Table 2. Our
diet method integrated the following key elements: 1) provision of foods accounting for two-
thirds of caloric intake; 2) bi-monthly diet counseling; 3) self-monitoring; and 4) an
intervention-specific website. All study participants were provided with, and instructed to
exclusively use low-LA oils and fat sources, including vegetable oils and salad dressings.
Because most US packaged food items contain substantial amounts of added LA,
participants were also provided with a variety of low-LA substitute foods, including
crackers, tortillas, breads and popcorn. Research foods were procured and prepared by the
UNC Nutrition Research and Metabolism Core of the Clinical and Translational Research
Center. Nutrient intakes were assessed using six unannounced telephone-administered 24-
hour recalls; three administered prior to the intervention, and three administered in the final
four weeks of the twelve-week intervention. Nutrient values were estimated using
Nutritional Data System for Research software in version 2009-2010, developed by the
Nutrition Coordinating Center, University of Minnesota, Minneapolis, MN [25].
Sample collection
Sample preparation and analyses were performed by investigators who were blinded to
study protocol and clinical data. Fasting blood was drawn at baseline and again after 12-
weeks of exposure to the dietary interventions. Whole blood was collected into
ethylenediaminetetraacetic acid (EDTA) tubes. Samples were immediately centrifuged at
2960 rpm for 15 min at room temperature. Plasma and erythrocyte aliquots were prepared
and immediately transferred to a − 80°C freezer until analysis. Analyses of OXLAMs,
plasma lipid fractions, and erythrocyte fatty acids were performed at the Cleveland Clinic
Department of Cell Biology, National Institute on Aging Brain Physiology and Metabolism
Section, and National Institute on Alcohol Abuse and Alcoholism Laboratory of Membrane
Biochemistry and Biophysics, respectively.
OXLAM analysis
Plasma OXLAMs were analyzed as previously described [3]. Briefly, plasma (50 μl),
internal standard [15(S)-HETE-d8, 10μL of 1000 ng/ml] and sodium hydroxide were added
to the glass test tubes, overlaid with argon, and sealed. Lipids were hydrolyzed at 60°C
under argon atmosphere for 2 h and then the released fatty acids were extracted into the
hexane layer twice by liquid/liquid extraction using hexane and hexane/isopropanol with 4M
acetic acid. With each extraction, tubes were capped under argon. The combined hexane
layers were dried under nitrogen gas and then re-suspended in 200 μl 85% methanol/water
(v/v). Fatty acid oxidation products (free plus esterified) in plasma were quantified using
liquid chromatography online electrospray ionization tandem mass spectrometry (LC/ESI/
MS/MS) (Fig. 2) [3]. Briefly, 40 μl of lipid extract was injected onto an HPLC (Waters
2690 Separations Module, Franklin, MA) system, and the oxidized fatty acids and their
precursors were separated through a C18 column (Phenomenex, ODS, 2 × 150 mm, 5 μm,
Rancho Palos Verdes, CA). The oxidized fatty acids and their precursors were quantified on
Ramsden et al. Page 3













a triple quadrupole mass spectrometer (Quattro Ultima, Micromass, Manchester, UK) using
ESI in negative ion mode and multiple reaction monitoring (MRM) using characteristic
parent → daughter ion transitions for the specific molecular species monitored. The lipid
peroxidation products analyzed included structurally specific species 9- and 13-HODE, 9-
and 13-oxoODE, and their precursor LA. 15-HETE-d8 (Cayman Chemical, Ann Arbor, MI)
was used as internal standard for calibration of oxidized fatty acids in plasma, as previously
described [3].
Fatty acid analysis
Plasma Fractions—Total lipids were extracted from 200 μl of plasma in 3 ml of 2:1
chloroform/methanol following the addition of unesterified heptadecaenoic acid (17:0) as an
internal standard (0.14 nmol/μl) for unesterified fatty acids. KCl (0.5M, 0.75 ml) was then
added to separate the aqueous phase. The bottom chloroform layer was separated and re-
extracted with 2 ml chloroform. The pooled extracts were dried down and separated into
neutral lipid subclasses using thin layer chromatography on silica gel-60 plates (EM
Separation Technologies, Gibbstown, NJ, USA). The lipid subclasses (total phospholipid,
triacylglycerol, cholesteryl ester, unesterified fatty acid) were separated using the solvent
system: heptane: diethylether: glacial acetic acid (60:40:3, v/v/v) [26]. Authentic standards
of the lipid classes were run on separate lanes on the plates to identify lipid bands under
ultraviolet light, after spraying with 0.03% 6-p-toluidine-2-naphthalene sulfonic acid in 50
mM Tris-HCl buffer (pH 7.4) (w/v). The bands were scraped into test tubes and methylated
with 1% H2SO4-methanol for 3 h at 70°C [27]. Before methylation, di-17:0 PC was added to
each tube as an internal standard for phospholipids, triglycerides and cholesteryl esters. The
prepared fatty acid methyl esters (FAME) were analyzed using a gas-chromatography
system (6890N, Agilent Technologies, Palo Alto, CA, USA) equipped with an SPTM-2330
fused silica capillary column (30 m × 0.25 mm i.d., 0.25 μm film thickness) (Supelco,
Bellefonte, PA, USA) and a flame ionization detector. Fatty acid concentrations were
calculated by proportional comparison of peak areas of samples to the area of the 17:0
internal standard.
Erythrocytes—Erythrocytes were obtained from EDTA blood samples after the plasma
and buffy coat were removed. Following Bligh/Dyer extraction [28], erythrocyte aliquots
were heated at 100°C for one hour with methanol containing 14% boron trifluoride to
generate FAME. These were then extracted into hexane and analyzed with a GC/FID gas
chromatograph (Agilent 6890) equipped with a 30-m DBFFAP capillary column. Fatty acids
were identified through comparison with a standard fatty acid methyl ester mixture
(GLC-462). Values are expressed as percentages of total red blood cell fatty acids.
Data Analysis—Non-parametric analyses were employed due to the presence of non-
normal distributions. Pre-to-post intervention comparisons were tested with the Wilcoxon
Signed-Rank test for matched pairs. A Mann Whitney U test was used for between group
comparisons. P values less than 0.05 were considered significant. In addition, in an
exploratory manner, Spearman’s coefficients were used to evaluate potential correlations
between circulating LA pools and OXLAMs.
Results
Lowering dietary LA from 6.7 to 2.4% of calories for 12-weeks in 55 patients with chronic
headaches significantly reduced the abundance of the four measured OXLAMs (9- and 13-
HODEs, 9- and 13-oxoODEs), as well as their precursor LA in circulating lipid pools (Table
2). There were no significant differences in OXLAM reductions between the two low-LA
intervention groups (Fig. 3), one with and one without added dietary n-3 fatty acids (Table
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1), indicating that the observed reductions were primarily due to the decrease in dietary LA.
The combined results of the two LA-lowering intervention groups are presented in Table 2.
Distinctions between OXLAM species and their precursor pools
Median reductions in the LA content of the four plasma fractions were significantly different
using Friedman ANOVA (p=0.02), with the most pronounced changes in the phospholipid
(PL) and triglyceride (TG) pools (Table 2). Unlike LA, the overall amount of total fatty
acids did not change in any of these plasma lipid fractions (Table 3). Although reductions in
oxoODEs tended to be more pronounced than HODEs (-18.3% vs. -12.0%), this difference
was not statistically significant (p=0.45).
Correlations between circulating LA pools and OXLAMs
Circulating OXLAMs correlated with the LA content of several OXLAM precursor pools at
baseline, and after the 12-week dietary intervention. At baseline, total OXLAMs correlated
with total plasma LA (Spearman rho(r)=0.48, p<0.01), as well as the LA content of
erythrocytes (r=0.28, p=0.04). Of the plasma lipid fractions, the strongest OXLAM
correlations were present in the phospholipid-LA (PL-LA) fraction (r=0.47, p<0.01),
however baseline TG-LA (r=0.28, p=0.04) and CE-LA (r=0.33, p=0.01) were also
significantly correlated with OXLAMs. After the 12-week intervention, total OXLAMs
remained correlated with total plasma LA (r=0.40, p<0.01), PL-LA (r=0.50, p<0.01), TG-
LA (r=0.37, p<0.01), and erythrocyte LA (r=0.42, p<0.01), but were no longer correlated
with CE-LA (r=0.15, p=0.27). OXLAMs were not correlated with FFA-LA before (r=0.01,
p=0.93) or after the dietary intervention (0.04, p=0.80).
Discussion
We report for the first time that lowering dietary LA reduces OXLAMs in humans, here
among subjects with chronic headaches. This link between dietary LA and OXLAMs may
have important implications for pathological conditions linked to increased activity or
abundance of OXLAMs (e.g. chronic pain, Alzheimer’s dementia, cardiovascular disease,
NASH) [1,2,3,15]. To our knowledge, this is the first demonstration that changes in dietary
LA can alter the abundance of plasma OXLAMs in humans, or that lowering dietary LA
reduces the abundance of OXLAMs in any tissue in a human or animal model. Our findings
are consistent with a report [29] that a 4-fold increase in dietary LA (from corn oil)
produced a 5-fold increase in the 9- and 13-HODE content of mammary tissue in female
mice. Collectively, these observations indicate that dietary LA may hold proximal control
over the production and/or accumulation of OXLAMs in certain tissues.
We also found that lowering dietary LA reduced the abundance of LA in several circulating
lipid fractions that may serve as precursor pools for endogenous OXLAM synthesis.
Importantly, the concentration of total fatty acids did not change in PL, TG, CE or FFA
(Table 3), indicating that observed reductions in LA and OXLAMs were unlikely to be
secondary to a general reduction in plasma lipoproteins. LA reductions were most
pronounced in the PL and TG fractions, indicating that these esterified fractions may be
particularly responsive to dietary modification. However, since the relative LA abundance
was reduced in all measured pools, and the LA content of other potential OXLAM sources
(e.g. liver, adipose) was not analyzed, it is not possible to attribute the observed OXLAM
reductions to any specific plasma lipid pool. Future studies using LA-tracers [30] and/or
tissue procurement for OXLAM analysis could help clarify the most relevant in vivo
OXLAM precursor pool(s).
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The robust correlations observed between circulating OXLAMs and LA in several LA pools
both at baseline and after the 12-week intervention are consistent with the hypothesis that
multiple LA pools contribute to in vivo OXLAM formation. The 12-week LA lowering
intervention may not have been of sufficient duration to establish a new steady state of CE-
LA in circulation. Consistent with this, there was a robust correlation between OXLAMs
and CE-LA at baseline was no longer present following the 12-week intervention.
Importantly, the CE pool contains about half of all circulating LA. Longer trials with serial
analyses of LA and OXLAMs may therefore help characterize the temporal relations
between diet-induced alterations in each circulating LA pool and OXLAMs.
Potential implications of dietary modulation of OXLAMs
OXLAMs are among the most abundant oxidized fatty acid derivatives in human plasma,
with >50-fold higher concentrations than the more extensively studied prostanoid and
isoprostane derivatives of arachidonic acid [15,31]. Unlike prostanoids however, OXLAMs
are readily incorporated into, and released from, esterified lipid pools including PL [32,33],
TG [34] and CE [11]. In rodents, plasma OXLAMs are largely esterified within lipoproteins
[10,35]. As a major component of oxidized LDL [7] as well as the foam cells and migrating
vascular smooth muscle cells found in atherosclerotic lesions [12,13], OXLAMs have been
implicated in cardiovascular disease (CVD) pathogenesis [4,8,9]. Therefore, the diet-
induced reductions in circulating OXLAMs demonstrated here may have clinical relevance
for CVD risk reduction.
If comparable reductions in the abundance of OXLAMs are achievable in other tissues,
dietary LA lowering may have diverse physiological and clinical consequences. Since LA is
the parent compound for OXLAM synthesis, diet-induced changes in tissue LA may induce
corresponding alterations in local OXLAM concentrations. Human and animal trials have
established that modifications in dietary LA alter the LA content of numerous tissue types
[36,37,38]. Sensitivities to alterations in dietary LA are likely to be tissue-specific
[39,40,41], with marked diet-induced alterations in the LA content of peripheral nerves [39],
small intestine [41], liver [39], testes [39], adipose tissue [37,39], and skeletal muscle
[39],and more modest changes in myelin and brain [39,40,42]. Remarkably, the abundance
of LA in rat sciatic nerve increased linearly from 3 to 15% of total fatty acids when dietary
LA was increased from 2 to 12% of energy [39]. In rodents, circulating LA readily crosses
the blood brain barrier [42], where the majority is quickly oxidized to unknown products. It
is presently unknown what proportion of these oxidized LA products are 9- and 13-HODEs
and oxoODEs.
Diet-induced modifications in the OXLAM content of neuronal tissues such as sciatic nerve
and brain may have important implications for conditions characterized by TRPV1
hyperactivity. OXLAM-mediated TRPV1 activation in rodents induced hyperalgesia and
allodynia [1,2], which was reversed with OXLAM specific immunological neutralization
[2], indicating that OXLAM-mediated signaling contributes to physical pain. Notably,
pathologies characterized by TRPV1 hyperactivity are common in tissues that readily
accumulate LA (e.g. fibromyalgia [43], irritable bowel syndrome [44,45], sciatica
[46]).While it is not yet known whether lowering dietary LA reduces neuronal and glial
OXLAM synthesis and accumulation, such a reduction would be expected to attenuate
TRPV1 activation[47], and ameliorate conditions characterized by TRPV1 hyperactivity
including physical pain. As TRPV1 is widely distributed in peripheral and central nervous
system tissues[48], the ability to modulate endovanilloid tone through diet could have broad
implications.
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In the United States, per capita dietary LA tripled from about 2% of energy (en%) to 7 en%
during the 20th century [49], which coincided with a marked increase in adipose tissue LA
[50,51,52]. Because human adipose tissue LA has a half-life of 1-2 years [36,53,54], the
gradual mobilization of LA from adipose stores into circulation is expected to lengthen the
time to steady state when lowering dietary LA. Hence, more robust OXLAM reductions may
be achievable by extending the duration of LA lowering dietary interventions beyond 12-
weeks. However, the chronic pain population studied here may have been especially
compliant due to the potential for pain relief. Therefore, the magnitude of OXLAM
reductions observed in this 12-week trial may not be readily achievable in other populations.
In conclusion, dietary LA lowering reduces circulating oxidized LA derivatives that have
been implicated in a variety of pathological conditions. Future studies evaluating the
metabolic and clinical implications of diet-induced OXLAM reductions are warranted.
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Figure 1. Oxidative metabolism of linoleic acid
LA can be enzymatically or non-enzymatically converted to 9- and 13-HpODE, with
subsequent enzymatic conversion to hydroxy (9- and 13-HODE) and ketone (9- and 13-
oxoODE) derivatives. The initial step (A) can be catalyzed by 12/15-lipoxygenase,
cyclooxygenase, or cytochrome P450 enzymes. Abbreviations: LA: linoleic acid; LOX:
lipoxygenase; COX: cyclooxygenase; HpODE; hydroperoxy-octadecadienoic acid; HODE:
hydroxy-octadecadienoic acid; oxoODE: oxo-octadecadienoic acid.
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Figure 2. Detection and quantification of OXLAM profile by ESI/LC/MS/MS
Individual isomers of HODEs and oxoODEs formed by LA oxidation were quantified with a
single injection. Lipid extracts were resolved by HPLC and monitored online by ESI/LC/
MS/MS [3]. Abbreviations: HODE: hydroxy-octadecadenoic acid; oxoODE, oxo-
octadecadenoic acid; 15-HETE-d8, internal standard.
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Figure 3. Comparable OXLAM reductions in the two LA lowering intervention groups
There were no between-group differences in the median reductions in HODEs, oxo-ODEs or
total OXLAMs, indicating that the observed changes were primarily due to the decrease in
dietary LA rather than the n-3 fatty acids provided only to Group 2. Data for the combined
groups are presented in subsequent tables and figures. The box-whisker plot is represented
with the lower boundary of the box indicating the 25th percentile, the line within the box
indicating the median value, and the upper boundary indicating the 75th percentile. The
whiskers extend to the non-outlier range. P values represent between group comparisons
using a Mann Whitney U test. Abbreviations: HODE: hydroxy-octadecadienoic acid; oxo-
ODE: oxo-octadecadienoic acid; OXLAM: oxidized linoleic acid metabolite.
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Table 2






Diet (% of energy)
Dietary LA 6.74 (5.54, 8.11) 2.42 (2.09, 3.06) −64.1 p<0.001
Plasma OXLAMs (nM)
9-HODE 266 (209, 365) 227 (182, 274) −14.7 p = 0.001
13-HODE 268 (229, 376) 243 (205, 294) −9.5 p < 0.001
Total HODEs 538 (442, 756) 474 (385, 564) −12.0 p < 0.001
9-oxoODE 169 (140, 229) 146 (116, 203) −13.8 p = 0.01
13-oxoODE 265 (213, 351) 204 (155, 273) −23.2 p < 0.001
Total oxoODEs 431 (353, 555) 352 (265, 478) −18.3 p < 0.001
Total OXLAMs 979 (823, 1310) 851 (693, 1007) −13.1 p < 0.001
Concentration of LA in plasma fatty acid pools (nmol/ml)
Total plasma LA 3075 (2622, 3357) 2615 (2249, 3038) −14.9 p < 0.001
Phospholipid-LA 813 (726, 941) 675 (593, 795) −17.0 p < 0.001
Triglyceride-LA 567 (337, 749) 395 (293, 548) −30.3 p < 0.001
Cholesteryl ester-LA 1592 (1429, 1816) 1440 (1191, 1665) −9.6 p = 0.002
Free fatty acid-LA 58 (36, 81) 53 (42, 69) −9.4 p = 0.35
Relative abundance of LA in circulating fatty acid pools (%Composition)
Phospholipid-LA 22.5 (20.9, 24.9) 20.0 (18.0, 21.7) −11.2 p < 0.001
Triglyceride-LA 20.6 (17.1, 24.1) 17.3 (14.8, 19.6) −16.0 p < 0.001
Cholesteryl ester-LA 55.5 (52.6, 58.5) 50.5 (46.7, 52.9) −9.1 p < 0.001
Free fatty acid-LA 16.0 (14.0, 18.0) 15.2 (13.6, 16.4) −5.2 p < 0.001
Erythrocyte-LA 12.0 (11.0, 12.7) 10.3 (9.3, 11.0) −14.5 p < 0.001
Pre-to-post comparisons of dietary LA (n=55), plasma OXLAMs (n=55), LA fractions (n=55), and erythrocytes (n=52) were analyzed with the
Wilcoxon Signed-Rank test for matched pairs. Blood collection was unsuccessful for one subject. Erythrocytes were not collected on four subjects.
Abbreviations: LA: linoleic acid; OXLAMs: oxidized linoleic acid metabolites; HODE: hydroxy-octadecadienoic acid; oxoODE: oxo-
octadecadenoic acid.
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Table 3











Total fatty acids 9512 (7784, 11586) 9552 (7978, 11394) +0.4 0.89
Total PL 3663 (3159, 4101) 3622 (3204, 3971) −1.1 0.43
Total TG 2519 (1679, 3563) 2479 (1692, 3422) −1.6 0.67
Total CE 2827 (2498, 3285) 2995 (2596, 3433) +6.0 0.46
Total FFA 342 (235, 441) 362 (275, 446) +6.0 0.63
Pre-to-post comparisons of total plasma fatty acids in plasma lipid classes were analyzed with the Wilcoxon Signed-Rank test for matched pairs.
Abbreviations: PL: phospholipid; TG: triglyceride; CE: cholesteryl ester; FFA: free fatty acids.
Prostaglandins Leukot Essent Fatty Acids. Author manuscript; available in PMC 2013 October 01.
